0001213900-22-007471.txt : 20220214
0001213900-22-007471.hdr.sgml : 20220214
20220214160049
ACCESSION NUMBER: 0001213900-22-007471
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220210
FILED AS OF DATE: 20220214
DATE AS OF CHANGE: 20220214
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Aberman Zami
CENTRAL INDEX KEY: 0001344740
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-31392
FILM NUMBER: 22631064
MAIL ADDRESS:
STREET 1: 63 RABUTZKY STREET
CITY: RAANANA
STATE: L3
ZIP: 43220
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PLURISTEM THERAPEUTICS INC
CENTRAL INDEX KEY: 0001158780
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 980351734
STATE OF INCORPORATION: NV
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: MATAM ADVANCED TECHNOLOGY PARK
STREET 2: BUILDING NO. 5
CITY: HAIFA
STATE: L3
ZIP: 3508409
BUSINESS PHONE: 972-74-710-7171
MAIL ADDRESS:
STREET 1: MATAM ADVANCED TECHNOLOGY PARK
STREET 2: BUILDING NO. 5
CITY: HAIFA
STATE: L3
ZIP: 3508409
FORMER COMPANY:
FORMER CONFORMED NAME: PLURISTEM LIFE SYSTEMS INC
DATE OF NAME CHANGE: 20030701
FORMER COMPANY:
FORMER CONFORMED NAME: AI SOFTWARE INC
DATE OF NAME CHANGE: 20010906
4
1
ownership.xml
X0306
4
2022-02-10
0
0001158780
PLURISTEM THERAPEUTICS INC
PSTI
0001344740
Aberman Zami
MATAM PARK, BUILDING #5
HAIFA
L3
3508409
ISRAEL
1
0
0
0
Common Stock
2022-02-10
4
P
0
80616
1.80
A
91756
I
By Rose Hitech Ltd.
Common Stock
1493973
D
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions on the Tel Aviv Stock Exchange in New Israeli Shekels (NIS), at per share purchase prices ranging from NIS 5.70 to NIS 5.90, inclusive, or ranging from $1.77 to $1.82 in U.S. Dollars, inclusive (based on an exchange rate of NIS 3.221 per U.S. dollar). The Reporting Person undertakes to provide to Pluristem Therapeutics Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).
/s/ Zami Aberman
2022-02-14